Edition:
India

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

52.96USD
18 Apr 2019
Change (% chg)

$1.37 (+2.66%)
Prev Close
$51.59
Open
$51.57
Day's High
$53.11
Day's Low
$50.83
Volume
144,856
Avg. Vol
147,014
52-wk High
$73.83
52-wk Low
$46.93

Latest Key Developments (Source: Significant Developments)

Emergent Biosolutions Reports Interim Results From Phase 2 Study Evaluating Its Chikungunya Virus Vaccine Candidate
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES INTERIM RESULTS FROM PHASE 2 STUDY EVALUATING CHIKV-VLP, CHIKUNGUNYA VIRUS VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS - UP TO 98% OF STUDY PARTICIPANTS PRODUCED A NEUTRALIZING ANTIBODY RESPONSE AGAINST CHIKUNGUNYA VIRUS (CHIKV) BY DAY 7.EMERGENT BIOSOLUTIONS INC - VACCINE CANDIDATE WAS WELL-TOLERATED ACROSS ALL STUDY ARMS.EMERGENT BIOSOLUTIONS INC - NO SIGNIFICANT VACCINE-RELATED SAFETY CONCERNS HAVE BEEN IDENTIFIED IN ANALYSES TO DATE.  Full Article

Emergent Biosolutions Awarded U.S. Department Of State Contract To Supply Medical Countermeasures For Chemical Warfare Agents
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED U.S. DEPARTMENT OF STATE CONTRACT TO SUPPLY MEDICAL COUNTERMEASURES FOR CHEMICAL WARFARE AGENTS.EMERGENT BIOSOLUTIONS INC - TOTAL CONTRACT VALUE OF A MINIMUM OF APPROXIMATELY $7 MILLION TO A MAXIMUM OF $100 MILLION OVER CONTRACT'S PERIOD OF PERFORMANCE.EMERGENT BIOSOLUTIONS INC - CONTRACT IS COMPRISED OF A FIVE-YEAR BASE PERIOD OF PERFORMANCE ALONG WITH FIVE ONE-YEAR OPTION PERIODS.  Full Article

Emergent Biosolutions Reports Fourth Quarter And Full Year 2018 Financial Results
Friday, 22 Feb 2019 

Feb 21 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.75.Q4 LOSS PER SHARE $0.07.Q4 REVENUE $270.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $270 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.65 -- REFINITIV IBES DATA.SEES Q1 2019 REVENUE $185 MILLION TO $205 MILLION.FOR FULL YEAR 2019, COMPANY REAFFIRMS ITS EXPECTATION.  Full Article

Emergent Biosolutions Announces Appointment Of Robert Kramer, Sr. To Its Board
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES APPOINTMENT OF ROBERT G. KRAMER, SR. TO ITS BOARD OF DIRECTORS.EMERGENT BIOSOLUTIONS -ROBERT KRAMER WILL ASSUME ROLE OF PRESIDENT AND CEO AND WILL SERVE ON THE EMERGENT BOARD, SUCCEEDING DANIEL J. ABDUN-NABI.EMERGENT BIOSOLUTIONS INC SAYS ROBERT KRAMER WILL ASSUME ROLE OF PRESIDENT AND CEO EFFECTIVE APRIL 1, 2019.  Full Article

Emergent BioSolutions Says Robert Kramer's Annual Base Salary Will Rise To $700,000 Upon His Starting As CEO
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS INC - KRAMER'S ANNUAL BASE SALARY WILL RISE TO $700,000 UPON HIS COMMENCING SERVICE AS CHIEF EXECUTIVE OFFICER.  Full Article

Emergent Biosolutions Says Daniel Abdun-Nabi To Retire As CEO
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES DANIEL J. ABDUN-NABI TO RETIRE AS CEO; ROBERT G. KRAMER, SR. TO BECOME PRESIDENT AND CEO.EMERGENT BIOSOLUTIONS INC - ABDUN-NABI HAS ALSO INDICATED THAT HE PLANS TO STEP DOWN AS A MEMBER OF EMERGENT BOARD.EMERGENT BIOSOLUTIONS - EXPECTS BOARD TO APPOINT KRAMER TO FILL BOARD VACANCY CREATED BY ABDUN-NABI'S RETIREMENT.  Full Article

Emergent Biosolutions Announces Submission To FDA Of Application Covering Emergency Use Authorization For Nuthrax™
Friday, 28 Dec 2018 

Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES SUBMISSION TO FDA OF APPLICATION COVERING EMERGENCY USE AUTHORIZATION FOR NUTHRAX™.EMERGENT BIOSOLUTIONS INC - SUBMISSION IS ANTICIPATED TO UNDERGO REVIEW BY FDA THROUGH FIRST HALF OF 2019..  Full Article

Emergent Biosolutions Q3 Adjusted Earnings Per Share $0.55
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 2018.Q3 ADJUSTED EARNINGS PER SHARE $0.55.Q3 EARNINGS PER SHARE $0.41.Q3 REVENUE $173.7 MILLION VERSUS I/B/E/S VIEW $184.1 MILLION.Q3 EARNINGS PER SHARE VIEW $0.58 -- THOMSON REUTERS I/B/E/S.REVISES FULL YEAR 2018 FINANCIAL FORECAST.SEES FY TOTAL REVENUES $715 -- $755 MILLION.SEES FY ADJUSTED NET INCOME $110 -- $125 MILLION.FY2018 EARNINGS PER SHARE VIEW $2.47, REVENUE VIEW $737.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Emergent Biosolutions Reports Q3 Earnings Per Share of $0.41
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 2018.Q3 ADJUSTED EARNINGS PER SHARE $0.55.Q3 EARNINGS PER SHARE $0.41.Q3 REVENUE $173.7 MILLION VERSUS I/B/E/S VIEW $184.1 MILLION.SEES FY TOTAL REVENUE $770 - $800 MILLION .SEES FY ADJUSTED NET INCOME $105 - $115 MILLION .Q3 EARNINGS PER SHARE VIEW $0.58 -- THOMSON REUTERS I/B/E/S.REVISES FULL YEAR 2018 FINANCIAL FORECAST.FY2018 EARNINGS PER SHARE VIEW $2.47, REVENUE VIEW $737.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Emergent Biosolutions Says To Maintain Narcan Pricing Established By Adapt
Wednesday, 29 Aug 2018 

Aug 28 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS SAYS WE EXPECT REVENUES IN 2019 TO BE BETWEEN $200 MILLION TO $220 MILLION- CONF. CALL.EMERGENT BIOSOLUTIONS SAYS TO MAINTAIN NARCAN PRICING ESTABLISHED BY ADAPT DURING LAUNCH; "NO PLANS TO CHANGE"- CONF. CALL.EMERGENT BIOSOLUTIONS SAYS TO MAINTAIN 40 PERCENT DISCOUNT FOR STATE AND LOCAL GOVERNMENTS AND NON PROFITS- CONF. CALL.EMERGENT BIOSOLUTIONS SAYS M&A CONTINUES TO BE A PRIORITY IN GROWTH APPROACH- CONF. CALL.  Full Article

Emergent-Valneva Zika vaccine clears early trial

A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.